ArticleMolecules (Basel, Switzerland)2025
The Biflavonoid Agathisflavone Regulates Microglial and Astrocytic Inflammatory Profiles via Glucocorticoid Receptor.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Molecular-Dynamics-Guided Screening Pipeline Identifies Topical Glucocorticoid Receptor Modulators with Selective Epidermal Activation.Skin pharmacology and physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Nuclear receptors such as glucocorticoid receptors (GRs) are transcription factors with prominent regulatory effects on neuroinflammation. Agathisflavone is a biflavonoid that demonstrates neurogenic, neuroprotective, anti-inflammatory, antioxidant, and pro-myelinogenic effects in vitro. This study investigated whether the control of glial reactivity by agathisflavone is mediated by GRs. Primary cultures of astrocytes and microglia were induced to neuroinflammation by lipopolysaccharides (LPSs) and exposed to agathisflavone or not in the presence or absence of mifepristone, a GR antagonist. The microglia morphology and reactivity were evaluated by immunofluorescence against calcium-binding ionized adapter (Iba-1) and CD68. The astrocyte morphology and reactivity were evaluated by immunofluorescence against glial fibrillary acidic protein (GFAP). The inflammatory profile was evaluated by RT-qPCR. Molecular docking was performed to characterize agathisflavone and GR interactions. Microglial branching was increased in response to agathisflavone, an effect that was inhibited by mifepristone. CD68 and GFAP expression was decreased by agathisflavone but not in the presence of mifepristone. Agathisflavone decreased the expression of the pro-inflammatory cytokine IL-1β and increased the expression of the regulatory cytokine IL-10. The increase in IL-10 mRNA was inhibited by the GR antagonist. The in silico analysis showed that agathisflavone binds to a pocket at the glucocorticoid receptor. These interactions were stronger than mifepristone, dexamethasone, and the agathisflavone monomer apigenin. These results indicate that the GR is involved in the regulatory effects of agathisflavone on microglia and astrocyte inflammation, contributing to the elucidation of the molecular mechanisms of agathisflavone's effects in the nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.